emerging-tech-investing DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
emerging-tech-investing DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
emerging-tech-investing DIAGNOS Appoints Dr. Ismail Ben Ayed as Chief Artificial Intelligence Scientist to Accelerate our Innovation in Healthcare
emerging-tech-investing Diagnos Announces Closing of Oversubscribed $4 Million Brokered Private Placement Led by Centurion One Capital
emerging-tech-investing Diagnos Announces Upsize of Previously Announced Brokered Private Placement to $3.65M Led by Centurion One Capital
emerging-tech-investing DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025
emerging-tech-investing DIAGNOS Announces $2.0 Million Brokered Private Placement Led by Centurion One Capital
emerging-tech-investing DIAGNOS Strengthens Governance and Leadership with the Appointment of Philippe Couillard as Chairman of the Board of Directors
emerging-tech-investing DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025
emerging-tech-investing Validated for Global Scale: DIAGNOS Passes Annual MDSAP Audit, Solidifying the Pathway to Approvals with Health Canada & FDA
